Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;289(1):116-120.
doi: 10.1111/joim.13156. Epub 2020 Jul 30.

COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

M F Landecho  1   2 , J R Yuste  1   2   3 , E Gándara  4 , P Sunsundegui  1   2 , J Quiroga  1   2   5 , A B Alcaide  1   6 , A García-Layana  4
Affiliations
Free article

COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease?

M F Landecho et al. J Intern Med. 2021 Jan.
Free article

Abstract

Importance: COVID-19 is caused by SARS-CoV-2, a betacoronavirus that uses the angiotensin-converting enzyme-related carboxypeptidase (ACE2) receptor to gain entry into cells. ACE2 receptor is widely expressed in multiple organs, including the retina, an extension of the central nervous system. The ACE2 receptor is involved in the diabetic and hypertensive retinopathy. Additionally, coronaviruses cause ocular infections in animals, including retinitis, and optic neuritis.

Objective: To assess whether there is any retinal disease associated with COVID-19.

Design: We have evaluated 27 asymptomatic subjects, with retinal fundoscopic, optical coherence tomography (OCT) and OCT angiography fourteen days after hospital discharge due to COVID-19 bilateral pneumonia.

Results: Cotton wool exudates were evident in six out of 27 patients evaluated, a 22%. Cotton wool exudates are a marker vascular disease severity in other medical context, that is diabetes and hypertension, and are associated with increased risk for acute vascular events. Whether antiaggregation therapy may play a role on fundoscopic-selected patients with COVID-19 requires prospective trials.

Keywords: COVID-19 retinal microangiopathy; COVID-19 retinopathy; COVID-19 vascular risk.

PubMed Disclaimer

References

    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46: 586-90.
    1. Verma A, Shan Z, Lei B et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther 2012; 20: 28-36.
    1. Duan Y, Beli E, Li Calzi S et al. Loss of angiotensin-converting enzyme 2 exacerbates diabetic retinopathy by promoting bone marrow dysfunction. Stem Cells 2018; 36: 1430-40.
    1. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020; 28: 391-5.
    1. Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R. Retinal findings in patients with COVID-19. Lancet 2020; 395: 1610.

LinkOut - more resources